Renaissance Capital logo

AERI News

Eye drop IPO Inotek Pharmaceuticals prices IPO at $6 per share

Inotek Pharmaceuticals, a biotech developing a small molecule eye drop therapy to treat glaucoma, raised $40 million by offering 6.7 million shares at $6.00 per share. At the offer price, it commands a fully diluted market value of $96 million. Insiders...read more

Blindness biotech blinks: Inotek Pharmaceuticals slashes proposed IPO valuation by 50%

Inotek Pharmaceuticals, a biotech developing a small molecule eye drop therapy to treat glaucoma, slashed the proposed price of its upcoming IPO on Tuesday. The Lexington, MA-based company now plans to raise $40 million by offering 6.7 million shares at a...read more

Rare eye disease biotech Applied Genetic Tech sets terms for $50 million IPO

Applied Genetic Technologies, a clinical-stage biotech developing treatments for orphan eye diseases, announced terms for its IPO on Wednesday. The Alachua, FL-based company plans to raise $50 million by offering 3.6 million shares at a price range of $13 to $15...read more

US IPO Recap: Twitter launches $1.3 billion IPO

Twitter (TWTR) launched the most anticipated IPO of the year last week, seeking to raise $1.3 billion at a price range of $17 to $20. Seven other companies, including retail chain The Container Store (TCS), also set terms. Four IPOs were completed, but only...read more